Form 8-K - Current report:
SEC Accession No. 0001213900-25-021184
Filing Date
2025-03-06
Accepted
2025-03-06 16:15:07
Documents
15
Period of Report
2025-03-05
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0233414-8k_abpro.htm   iXBRL 8-K 33184
2 WARRANT ADJUSTMENT NOTICE DATED MARCH 6, 2025 ea023341401ex99-1_abpro.htm EX-99.1 12309
  Complete submission text file 0001213900-25-021184.txt   269244

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE abp-20250305.xsd EX-101.SCH 3855
4 XBRL DEFINITION FILE abp-20250305_def.xml EX-101.DEF 26756
5 XBRL LABEL FILE abp-20250305_lab.xml EX-101.LAB 36996
6 XBRL PRESENTATION FILE abp-20250305_pre.xml EX-101.PRE 25380
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0233414-8k_abpro_htm.xml XML 5990
Mailing Address 6 ST JOHNS LANE, FLOOR 5 NEW YORK NY 10013
Business Address 6 ST JOHNS LANE, FLOOR 5 NEW YORK NY 10013 248-890-7200
Abpro Holdings, Inc. (Filer) CIK: 0001893219 (see all company filings)

EIN.: 871013956 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41224 | Film No.: 25715417
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)